Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2022 Oct 4;17(10):e0272097. doi: 10.1371/journal.pone.0272097

Physiology of PNS axons relies on glycolytic metabolism in myelinating Schwann cells

Marie Deck 1,*, Gerben Van Hameren 1, Graham Campbell 1, Nathalie Bernard-Marissal 2, Jérôme Devaux 1, Jade Berthelot 1, Alise Lattard 1, Jean-Jacques Médard 3, Benoît Gautier 1, Sophie Guelfi 1, Scarlette Abbou 1, Patrice Quintana 1, Juan Manuel Chao de la Barca 4,5, Pascal Reynier 4,5, Guy Lenaers 5, Roman Chrast 3, Nicolas Tricaud 6,*
Editor: David J Schulz7
PMCID: PMC9531822  PMID: 36194565

Abstract

While lactate shuttle theory states that glial cells metabolize glucose into lactate to shuttle it to neurons, how glial cells support axonal metabolism and function remains unclear. Lactate production is a common occurrence following anaerobic glycolysis in muscles. However, several other cell types, including some stem cells, activated macrophages and tumor cells, can produce lactate in presence of oxygen and cellular respiration, using Pyruvate Kinase 2 (PKM2) to divert pyruvate to lactate dehydrogenase. We show here that PKM2 is also upregulated in myelinating Schwann cells (mSC) of mature mouse sciatic nerve versus postnatal immature nerve. Deletion of this isoform in PLP-expressing cells in mice leads to a deficit of lactate in mSC and in peripheral nerves. While the structure of myelin sheath was preserved, mutant mice developed a peripheral neuropathy. Peripheral nerve axons of mutant mice failed to maintain lactate homeostasis upon activity, resulting in an impaired production of mitochondrial ATP. Action potential propagation was not altered but axonal mitochondria transport was slowed down, muscle axon terminals retracted and motor neurons displayed cellular stress. Additional reduction of lactate availability through dichloroacetate treatment, which diverts pyruvate to mitochondrial oxidative phosphorylation, further aggravated motor dysfunction in mutant mice. Thus, lactate production through PKM2 enzyme and aerobic glycolysis is essential in mSC for the long-term maintenance of peripheral nerve axon physiology and function.

Introduction

Energetic metabolism is an essential parameter of neurons’ function and survival [13]. Indeed, the nervous system consumes a large amount of glucose mainly to allow synapses to function but also organelles and vesicles transport along axons and action potentials firing [1]. In the peripheral nervous system (PNS), axons grow far from their cell bodies to reach distant targets such as muscles. Maintaining metabolic homeostasis on such a long distance is a real challenge for peripheral nerve axons [4].

To support neurons in this challenge, myelinating Schwann cells (mSC) cover the large motor axons with a myelin sheath. This insulating sheath, resulting from several turns of compacted plasma membrane, allows for ionic and electronic insulation forcing action potentials to “jump” from one node of Ranvier to the next, accelerating the nerve conduction velocity up to 120m/s [5]. Unfortunately, this insulation also hinders the diffusion of extracellular metabolites in the axonal environment mechanically limiting metabolic support to myelinated axons.

However, glial cells have also been shown to provide a direct trophic support to the axons they surround. Indeed, evidence exist for a metabolic coupling between glial cells and neurons in the CNS. Astrocytes and oligodendrocytes play a critical role in this process by metabolizing glucose into lactate and exporting it to the axon as a fuel for axonal mitochondria, a process known as the lactate shuttle [68]. Recently, mitochondrial respiration was shown to be dispensable for myelinating oligodendrocytes suggesting these cells can use glycolysis for ATP production and produce lactate [7, 9]. The disruption of monocarboxylate transporters (MCT), which mediate the traffic of metabolites, induced motor endplate dysfunction [10, 11], axonal damages and the degeneration of neurons in vivo [8, 12].

Lactate production in aerobic conditions has been well studied in cancer cells. Indeed, many type of cancer cells use aerobic glycolysis, also called the Warburg effect, to produce ATP as well as other metabolites required for cell survival and proliferation [13]. This metabolic shift to the aerobic glycolysis relies on the expression of Pyruvate Kinase M2 (PKM2) isoform instead of PKM1 [14]. PKM2 is a master regulator of glycolysis cumulating metabolic and non-metabolic functions as a protein kinase and transcriptional coactivator [15]. How PKM2 expression leads to more lactate is not clear. However, as PKM2 slows down pyruvate synthesis compared to PKM1, this may allow lactate dehydrogenase to metabolize pyruvate into lactate [1517].

Recently, cases of reversible peripheral neuropathy have been observed following treatment with dichloroacetate (DCA), a chemical compound acting on lactate level in cells [18, 19]. Indeed, DCA is indirectly activating pyruvate dehydrogenase (PDH) and increasing the mitochondrial uptake of pyruvate, depleting cellular lactate. While the use of this compound to prevent cancer cells growth in several tumors is controversial [19, 20], it is also indicated to treat acute and chronic lactic acidosis and diabetes [21]. DCA side effects suggest the importance of lactate balance in the PNS function.

Here, we investigated the role of lactate in the physiology and function of axons and mSC of the PNS through the deletion of PKM2 in mSC (mSC–PKM2). Our results revealed the delicate equilibrium of lactate homeostasis in myelinated fibres of peripheral nerves and the critical trophic role of mSC in the support of axonal function in PNS.

Material and methods

Animals

Schwann cell specific ablation of PKM2 in adult mice (Plp1-creERT;PKM2f/f) was obtained by crossing Plp1-creERT (JAX: 005975) [22] mice with PKM2f/f (JAX: 024048) [14] to generate Plp1-CreERT;Pkm2+/f animals, which were in turn backcrossed with PKM2f/f mice. Plp1-creERT mouse line was chosen because it is the only commercially available line allowing selective and inducible recombination in myelinating Schwann cells. All transgenic lines were kept in C57/Bl6 background. Genotyping for all mutants was performed by PCR strategies using standard procedures and appropriate primers from Jackson Laboratories. Animals were kept under French and EU regulations, following recommendations of the local ethics committee (#2019020908408066). Sacrifice was done after sedation with an overdose of CO2.

Tamoxifen administration

The recombination of the floxed allele was induced by intraperitoneal injection of tamoxifen (Sigma, T-5648) dissolved in corn oil (Sigma, C-8267) once every 24 hours for a total of 5 consecutive days, in 1 month animals at 180 μg/ gram mouse weight.

DCA administration: dichloroacetate (DCA, Sigma, D-54702) dissolve in water was administrated by gavaging six days per week during seven weeks, at 500 mg/ kg mouse weight.

Behavioural studies

Rotarod tests

Locomotor coordination was performed with a rotating rod apparatus (Bioseb). Mice from 2 to 12 month were placed on the rotating rod and challenged using the following step: on day 1, mice was familiarized to the behavioral room and learned to stay on the Rotarod at constant speed of 8 rpm for 2 min. At day 2, locomotion performance was assessed on the accelerating Rotarod with a rate of 4 to 40 rpm for 2 min. Latency to fall was recorded on 3 trials separating by at least 15 min pauses. Data are expressed as the means from the 3 trials for each animal, normalized according to animal weight, +- standard error of the mean (SEM).

Griptest

Muscular strength for the 4 limbs was assessed with a grip test apparatus (Bioseb). Mice were held by the tail and allowed to grab the grid and then pulled backwards in a horizontal plane. The maximum force (measured in Newtons) applied to the grid was recorded. Data are expressed as the means from 3 trials for each animal, normalized according to animal weight, +- standard error of the mean (SEM).

Motor nerve conduction velocity measurement

Mice were anesthetized with 2% isoflurane and maintained at 37°c on a hotplate. Left and right sciatic nerves were successively stimulated at the sciatic notch (proximal stimulation) and the ankle (distal stimulation) via a pair of steel needle electrodes (AD Instruments, MLA1302) with supramaximal pulses (7V) of 0.05 milliseconds delivered using a PowerLab 26T (AD Instruments ML4856). The distance between the 2 sites of stimulation was measured alongside the skin surface with fully extended legs. The latencies of the CMAP were recorded with a second pair of electrodes inserted between the digits of the hind paw and measured from the stimulus artefact to the onset of the M-waves deflection. NCV was calculated by dividing the distance between sciatic notch and ankle sites of stimulation by the subtraction of the distal latency from the proximal latency.

Immunohistochemistry

For immunohistochemistry on cryosection, nerves were dissected and fixed 2hours in PFA4% at 4°C. For spinal cord and DRG, mice were first perfused transcardially with PBS, and spinal cord and DRG were dissected and fixed in PFA4% overnight or 10min respectively. All tissues were then transferred to 30% sucrose overnight before embedding into Optimum Cutting Temperature (OCT, Tissue-Tek) medium. Cryostat sections of nerves or spinal cord (12 μm) were dried at room temperature (RT) for 15 min, washed in PBS, incubated 1h at RT in a blocking solution (0.25% Triton X-100 and 10% normal Goat serum in PBS) and incubated with primary antibodies in blocking solution overnight at 4°C. For immunochemistry on teased fibers, nerves were isolated from mice, fixed for 10 min in Zamboni’s fixative, washed in PBS and subsequently teased on glass slides. Slides were then dried overnight at RT and immunostained as described above. Primary antibodies: PKM1: 1/2500 (NBP2-14833, Novus Biologicals); PKM2 1/500 (SAB4200095, Sigma Aldrich); 2H3:1/80 (DSHB); Cleaved caspase3 1/400 (Cell Signaling); Neurofilament SMI32 1/1000; E-Cadherin 1/300 (MABT26, Merck); SV2 1/100 (DSHB). Secondary donkey antibodies coupled to Alexa Fluor 488, Alexa Fluor 594, or Alexa Fluor 647 1/1000 (Invitrogen) and DAPI 1/1000 (Molecular Probes). Imaged were acquired with a Zeiss confocal microscope LSM710.

For neuromuscular junctions immunostaining, gastrocnemius muscles were dissected and fixed 20 minutes in PFA4% and incubated in 25% sucrose solution at 4°C for 24 h. Tissues were embedded in OCT and stored at -80°C before processing. Neuromuscular Junctions (NMJ) occupancy was quantified on 25-μm thick longitudinal gastrocnemius sections. Muscle sections were incubated overnight at 4°C in blocking solution (2% BSA, 10% NGS, 0.1% Triton and PBS) with mouse anti-SV2 (Developmental Hybridoma Bank, 1/50). Sections were next incubated with goat anti-mouse IgG1 Cy3-conjugated antibody (Jackson ImmunoResearch, 1/500) and Bungarotoxin-488 (Molecular Probes, 1/500), and mounted in Mowiol mounting medium. NMJ were imaged on Axioplan fluorescence microscope (Zeiss) with a 20x objective.

Images that did show at least 5 Neurofilament positive cells were not included in the statistical analysis.

Histology staining

Cresyl violet staining was undertaken on PFA perfused spinal cord. Cresyl violet solution was prepared with 0.1g cresyl violet acetate in 100ml distilled water and 250μl glacial acetic acid and filtered before use. Slides were kept at -20˚C and removed one hour before staining. Sections were rinsed 2 times in PBS for 5 minutes and for 1 minute in distilled water. Sections were put in pre-warmed (45 ˚C) cresyl violet solution for 20 minutes. Slides were then rinsed 2 times for 5 minutes in distilled water, followed by a 3 minute rinse in 90% ethanol and then 100% ethanol and cleared in xylene. Slides were mounted in DPX. Brightfield images were taken on a Zeiss Imager.D2 at 10 x magnification. Motor neurons were identified by morphology and size.

Electron microscopy

Sciatic nerves were isolated from mice and immediately fixed in 2.5% glutaraldehyde and 4% PFA for 2h at RT, and postfixed in 2.5% glutaraldehyde in PHEM buffer (1X, pH 7.4) overnight at 4°C. They were then rinsed in PHEM buffer and post-fixed in a 0.5% osmic acid for 2h at dark and room temperature. After two washs in PHEM buffer, the cells were dehydrated in a graded series of ethanol solutions (30–100%). The cells were embedded in EmBed 812 using an Automated Microwave Tissue Processor for Electronic Microscopy, Leica EM AMW. Thin sections (70 nm; Leica-Reichert Ultracut E) were collected at different levels of each block. These sections were counterstained with uranyl acetate 1.5% in 70% Ethanol and lead citrate and observed using a Tecnai F20 transmission electron microscope at 200KV in the CoMET MRI facilities, INM, Montpellier France.

Semithin (1 μm) cross section were stained with toluidine blue (Sigma-Aldrich, 89640-5G) and observed with a Nanozoomer Hamamatsu. The g-ratio was determined using the ImageJ GRatioCalculator plug-in (CIF, UNIL).

Metabolomic

Sciatic nerves of 4 months mice were dissected and immediately frozen in liquid nitrogen until metabolomics analysis. Samples were homogenized with 2 grinding cycles, each at 6600 rpm for 20 sec, spaced by 20 sec, using a Precellys homogenizer (Bertin Technologies, Montigny-le-Bretonneux, France) kept in a room at +4°C. The supernatant was recovered after centrifuging the homogenate and kept at -80°C until mass spectrometric analysis. Targeted metabolomic analysis was carried out using the AbsoluteIDQ kit p 180 (Biocrates Life Sciences AG, Innsbruck, Austria). This kit standardizes mass spectrometry quantification (Sciex QTRAP 5500 AB mass spectrometer, SCIEX, Villebon-sur-Yvette, France) of 188 metabolites including 40 acylcarnitines, 21 amino acids, 21 biogenic amines, 90 glycerophospholipids, 15 shingolipids and the sum of hexoses. The full list of individual metabolites is available at http://www.biocrates.com/products/research-products/absoluteidq-p180-kit. Flow injection analysis coupled with tandem mass spectrometry (FIA-MS/MS) was used for the analysis of carnitine, acylcarnitines, lipids and hexoses. Liquid chromatography (LC) was used for separating amino acids and biogenic amines before quantitation with mass spectrometry. Before statistical analysis, the raw metabolomics data were examined to exclude metabolites with more than 20% of concentration values below the lower limit of quantitation (LLOQ) or above the upper limit of quantitation (ULOQ). Before performing statistical analyses, data from each sample were normalized by the total ion current (TIC).

To determine if molecule content variations reflected differences in metabolism in between Wild-Type, control and mutant mice, we carried out a Principal Component Analysis (PCA) by using the R-package ade4 [23]. This method is a classically used ordination method to summarize the patterns of variations among a large collection of samples, as it is well suited to contingency tables. As female’s metabolism is more hormonal dependent than male, we excluded female mice to remove noise in the PCA. We thus performed the PCA on 15 male mice (5 WT, 5 controls and 5 mutants) with the full dataset of 161 molecules. Then we analyzed acylcarnityls profiles in control mutant and mutant mice using a paired two-tailed T-tests.

Lactate assay

To measure lactate content in sciatic nerves and forebrain of Control and Mutant animals, equal amounts of tissue were dissected and immediately homogenized with Lysing Matix D tubes (MP Biomedical) in the lactate assay buffer and proceed according the instruction of the lactate assay kit (MAK064, Sigma-Aldrich).The absorbance at 570 nm was measured with microplate reader (CLARIOstar, BMG Labtech)

Western blot

Sciatic nerves were dissected from mice, after removal of the epineurium and perineurium, the nerves were frozen in liquid nitrogen and conserved at -80°C. Protein were extracted from whole sciatic nerves after homogenization by sonication in standard RIPA lysis buffer and the protein concentration was measured using a BCA protein assay kit (Pierce). 20 μg proteins were directly analyzed by western blot using standard procedures with 12% SDS–PAGE and transferred on PVDF membranes for immunoblotting. Primary antibodies: Rabbit anti-Pkm1 1/2500 (NBP2-14833, Novus Biologicals); Rabbit anti-Pkm2 1/2500 (SAB4200095, Sigma Aldrich); Mouse anti-α-β-Actin 1/10000 (C1.AC-15, #A1978, Sigma Aldrich). Secondary antibodies, Peroxidase Goat anti Rabbit or Mouse (H+L) (Jackson Immuno Research) were used at 1/10000 dilution.

Semi-quantitative rtPCR

Whole sciatic nerves from 2 and 10 days old mice (P2 and P10) or endoneuria from 1 (P28), 3 and 12 months-old mice were dissected at indicated time-points. Tissues were lysed using Trizol reagent and mechanical homogenization (TissueLyser II, Qiagen). Total RNA was extracted with the RNeasy lipid tissue kit (Qiagen), and RNA quality and concentration were verified by ND-1000 spectrophotometer (NanoDrop). cDNA was synthesized using 70-200ng of the RNA with the PrimeScript RT kit (Takara), following manufacturer’s protocols. PKM1 and PKM2 splicing assays at different developmental time-points were conducted as previously described [24] using the following primers PKM-F: 5’-ATGCTGGAGAGCATGATCAAGAAGCCACGC-3’ and PKM-R: 5’-CAACATCCATGGCCAAGTT-3’ with PCR annealing step at 60°C during 35 cycles and using HotStart Taq Polymerase (Qiagen). Digestions of cleaned 502bp-PCR products (with DNA Extraction kit, Qiagen) by NcoI (NEB), producing approx. 250 bp bands revealing PKM1 transcript, and PstI (NEB), producing approx. 280+220 bp bands revealing PKM2 transcript), were performed for 2h at 37°C. Digested PCR products were resolved on a 2% agarose gel, imaged by ChemiDoc XRS+ system and quantified using Image lab software version 3.0 (Biorad). The ratio between detected intensity of uncut and cut products was used to assess relative amount of PKM1 and PKM2.

Probes construction and AAV preparation

pAAV-Laconic and pAAV-δGlu6 were obtained by digesting Laconic/pcDNA3.1(-) (gift from Luis Felipe Barros; Addgene plasmid #44238) [25] and pcDNA3.1 FLII12Pglu-700uδ6 (gift from Wolf Frommer; Addgene plasmid # 17866) [26] by BamH1/HindIII (NEB) and cloned into pAAV-MCS (Cell Biolabs, Inc.) under of a CMV promoter. Clones were validated by sequencing. pcDNA-mito-AT1.03 (from H. Imamura, Tokyo, Japan) [27] was digested with XhoI/HindIII (NEB), blunted and cloned into the CMV promoter controlled pAAV-MCS. Mitochondria-targeting tags were two tandem copies of CoxVIII. pAAV9 were produced at UPV, Universitat Autonoma de Barcelona or at INSERM U1089 University of Nantes, France.

In vivo injection in spinal cord

The pups between 1 and 3 days were covered in aluminum foil and completely surrounded in ice for 3–4 min, until a completely cryoanesthetizia. Cryoanesthetized neonates were injected using a thin glass needle filled with colored viral and hold by a micromanipulator (IM—3C, Narishige Japan Group) directly in the spinal cord. 1 μL of the viral solution was injected slowly with short pressure pulses using a microinjector (Pneumatic Picopump PV820, World Precision Instruments) coupled to a 3 MHz function pulse generator (GFG8215, Langlois). The injection site was then cleaned with betadine (Vetoquinol, cat. No. 3042413) and pups were warmed in hands. When fully awake, pups were put back to the mother and the littermates.

Imaging and stimulation of saphenous nerves in living mice

3–4 weeks after the viral injection, mice were anesthetized with a constant low (1.5 l/min) of oxygen+ 5% of isoflurane in an anesthesia induction box (World precision Instrument, Ref.EZ-B800) for 5 min. Thereafter the anesthesia was maintained with a mask delivering 2% isoflurane at 0.8 L/min. The eyes were protected with Ocry-gel (TVM, cat. No. 48026T613/3). The mouse was placed on the back in a silicone mold, the hind leg was shaved and the paws were immobilized using small pins. The incision area was disinfected with betadine (Vetoquinol, cat. No. 3042413). After incision of the skin of the thigh, connective tissue was carefully removed to expose the saphenous nerve. For electrophysiological experiments, the saphenous nerve was lifted up in the middle of the thigh and isolated electrically from the surrounding muscle tissue using a plastic trip. A pair of stimulating platinum electrodes (World precision Instrument, PTM23B05KT) held by micromanipulators (U-31CF, Narishige) was carefully placed under the saphenous nerve, at the ankle. The recording electrode (AD Instruments, MLA 1203) was placed at the groin. A reference needle electrode was inserted in the groin area and a ground electrode is placed in the tail. Once the electrodes were positioned the animal was transferred in a chamber at 37°C under the two-photon microscope (LSM 7 MP OPO, Zeiss), electrodes are connected to a Powerlab 26T (AD Instrument; ML4856). Supramaximal stimulus (between 4 and 12 mA, 150 μs) was delivered at a frequency of 10 Hz during 5 min [28]. Time-lapse of the middle portion of the exposed nerve in the thigh were acquired every 5 min during 1 h with 20X objective lens (LD CApochromat, 421887–9970, Zeiss. For Laconic, δGlu6, and mito-ATeam alike, a 870 nm excitation wavelength was used to obtain both emission wavelength 475 nm for mTFP (Laconic) or CFP (δGlu6, mito-Ateam) and emission wavelength 527 nm for Venus (Laconic, mito-ATeam) or YFP (δGlu6).

Image analysis

We used ImageJ software to analyze the relative lactate, glucose or mitochondrial ATP levels in peripheral axons. The acquired images for each wavelength (em. 475 nm for mTFP or CFP and em. 527 nm for Venus or YFP) were aligned using the Template Matching plugin. We defined a Region of Interest (ROI) encompassing the cytosolic area of one axon or encompassing all labelled mitochondria of one axon and the mean fluorescent intensity in the ROI was measured on both images. These light intensities were then corrected for background light intensity determined as an area within the nerve where no fluorescent signal from the viral probe can be observed. The Citrine/CFP (δGlu6) or Venus/mTFP (Laconic) or Venus/CFP (mito-Ateam) ratio was then calculated from the 2 values for mean light intensity.

The MTrackJ plugin in ImageJ was used for analysis of mitochondrial movement. For at least 5 images over a time span of 20 minutes, the location of the same mitochondrion was marked, the distance between marked locations was measured and migration velocity was calculated. n = 65 (Control before stimulation), 75 (Mutant before stimulation), 76 (Control after stimulation), 45 (Mutant after stimulation) mitochondria.

Ex vivo nerve electrophysiology

Sciatic nerves were dissected out and transferred into oxygenated artificial cerebrospinal fluid (ACSF) containing 126 mM NaCl, 3 mM KCl, 2 mM CaCl2, 2 mM MgSO4, 1.25 mM NaH2PO4, 26 mM NaHCO3, and 10 mM dextrose, pH 7.4–7.5. The nerves were desheated, and cut into 2 cm segments. Nerves were then placed in a three compartment recording chamber and perfused (1–2 ml/min) in 36°C ACSF equilibrated with 95% O2-5% CO2. The distal end was stimulated supramaximally (40 μs duration) through two electrodes isolated with Vaseline, and recordings were performed at the proximal end. Signals were amplified and digitized at 500 kHz. Measurements were made once the effects had reached a steady state. The delay and duration of compound action potentials (CAPs) were calculated at half the maximal amplitude and at the maximal amplitude. For recruitment analysis, the amplitude of CAPs was measured and plotted as a function of the stimulation intensity. For refractory period analysis, two stimuli were applied at different intervals, and the amplitude of the second CAP was measured and plotted as a function of the stimulus interval. To ensure that the amplitude of the second response was accurately assessed, the first response was subtracted from all the recordings. For train stimulation, nerves were stimulated for 200ms at frequencies ranging from 100 to 1 kHz. The amplitude of each evoked CAP was measured and plotted as a function of time. Conduction velocities were estimated from latencies.

Statistical analysis

Except indicated otherwise, statistical analysis were done using Graphpad Prism (GraphPad Software, San Diego, USA). Statistical significance: * = P value<0.05; ** = P value<0.01; *** = P value<0.001.

Results

PKM2 expression promotes aerobic glycolysis in mSC

Firstly, to investigate the metabolic status of SC, we examined the expression and localization of PKM1 and PKM2 isoforms in mouse sciatic nerves using RT-qPCR and immunohistochemistry. PKM1 mRNA was downregulated during sciatic nerve maturation from postnatal day (P) 2 to P28 while PKM2 expression increased at the same time (Fig 1A). At non mature ages of SC, P4 and P15, PKM1 and PKM2 were both expressed in mSC (characterized by E-cadherin staining) [29] that surrounded axons (characterized by 2H3 staining, Fig 1B a, b, c, d). When SC were mature and formed myelin, at P30 and 5 months, PKM2 replaced PKM1 in mSC (Fig 1B e, f, g, h), in particular in the perinuclear region (S1 Fig in S1 File), suggesting mSC enters the aerobic glycolysis metabolic mode when the myelinated fibers are mature.

Fig 1. PKM2 is efficiently deleted in mature mSC of mutant mice.

Fig 1

A- Quantitative RT-PCR on sciatic nerve extracts shows decreased PKM1 and increased PKM2 expressions during mSC maturation. Normalized on P2 values. n = 4 animals. B- Immunostaining on mouse sciatic nerve sections at increasing ages (a, b: 4 days postnatal (d); c, d: 15 days postnatal; e, f: 30 days postnatal; g, h: 5 months postnatal (m)) shows decreased PKM1 (left panels) and increased PKM2 (right panels) expressions in mSC over time. m: months. Sc: Schwann cell; a: axon. C- Western blots on sciatic nerve extracts show lower PKM2 and higher PKM1 amounts in Mutant versus Control mice sciatic nerves (2 months old). Actin serves as loading control. n = 3 mice. D- Quantitative RT-PCR on sciatic nerve extracts shows decreased PKM2 and increased PKM1 expressions in Mutant (Mut, n = 7) versus Control (Cont, n = 5) mouse sciatic nerves (samples from 3 and 12 months old mice were pooled). E- Immunostainings on sciatic nerve sections show PKM2 lower in Mutant mSC than in Control mice (panel j vs panel l) while PKM1 is higher (panel i vs panel k)(2 months old). F- The ratio of Laconic probe was measured in mSC of Mutant (n = 11 mice, 41 cells) and Control (n = 11 mice, 45 cells) anesthetized mice and normalized to the mean of Control values (7 to 10 weeks old mice). G-Biochemical measure of lactate shows a reduced concentration in Mutant versus Control sciatic nerves (n = 6 mice)(samples from 4 and 12 months old mice were pooled). All scale bars = 10μm. Two-tailed Student t-test. Error bars represent SD (A, D) or SEM (F). AU: arbitrary unit.

PKM2 deletion in mSC leads to a reorganization of the metabolism in the nerve

The detected expression of PKM2 in mature mSC suggested that they were producing lactate, which raised the possibility that they provided a trophic support to axons. To test this hypothesis, we first performed a time-restricted conditional deletion of PKM2 isoform in myelinating glia of mice. A mouse strain expressing floxed PKM2-specific exon 10 alleles [14] was crossed with a strain expressing the Cre recombinase under the inducible and myelinating cell-specific promoter PLP1-ERt [22]. Injecting tamoxifen in Cre positive/PKM2fl/fl (mutant) and Cre-negative/PKM2fl/fl (control) littermates at 1 month of age resulted in a significant decrease of PKM2 expression in sciatic nerves of mutant as detected by immunoblotting, quantitative RT-PCR and immunostaining (Fig 1C–1E). The same experiments indicated that PKM1 was re-expressed in PKM2-deleted mSC (Fig 1D and 1E), suggesting a compensatory mechanism to maintain energy production.

Next, we expressed a lactate-detecting fluorescent probe (Laconic, S2 Fig in S1 File) in mSC of the mouse sciatic nerve in vivo using an AAV9 vector [30]. Mutant and control mice expressing the probe were then anesthetized and their nerves imaged using a multi-photon microscope to measure the relative amount of lactate in mSC of living mice. Cells of mutant mice showed significantly less lactate than mSC of control mice (Fig 1F). In addition, biochemical measurements showed that this deficit of lactate in mSC resulted in a global reduction of the amount of lactate in mutant mice nerves compared to control ones (Fig 1G). At the opposite, while PKM2 is also expressed in CNS oligodendrocytes [31], the amount of lactate in the frontal part of the mouse brain was not altered in mutant versus control mice (S3 Fig in S1 File), suggesting that PKM2 deletion has a limited impact on the CNS metabolism and function.

To analyze in a broader way the influence of PKM2 deletion in mSC on the metabolic status of the nerve, we performed a targeted metabolomic screen on mutant and control mouse nerves. We observed a decrease of some acylcarnitines in mutant mice (S4 Fig in S1 File), without modification of the acylcarnitine/carnitine ratio (0.2707 vs 0.2739 in control and mutant respectively, P = 0.77 two–tailed Student T-test). These acylcarnitines are involved in the transport of fatty acids across mitochondrial membranes before their degradation in carnitine and acetyl-CoA [32]. Therefore, the maintenance of the ratio coupled to the decrease of acylcarnitines indicated a higher turnover, suggesting an increase of the mitochondrial activity. Moreover, as mitochondrial dysfunction following deletion of TFAM1 (Transcriptional Factor A Mitochondrial 1) in mSC of mice has been shown to dramatically increase acylcarnitines [33], our data suggested the opposite effect in mutant mice, i.e. the upregulation of mitochondrial activity.

Lactate homeostasis and ATP production are impaired in axons of PKM2-SCKO mice

According to the lactate shuttle theory, this decrease of lactate should also result in a shortage of axonal lactate. We investigated this assumption by expressing Laconic in peripheral axons using an AAV9 vector injected intrathecally in young pups (S5A Fig in S1 File). After tamoxifen induced recombination we performed live-imaging of probe-labeled axons that cross the saphenous nerve in anesthetized mice (S5A Fig in S1 File). The sensory saphenous nerve was chosen over more heavily myelinated nerves to prevent motor reflexes to alter imaging upon stimulation. While in resting conditions no difference could be seen between genotypes (S6A Fig in S1 File), when nerves were challenged with physiologically-relevant electrical stimulations to generate action potentials in type A fibers, axonal lactate increased shortly after the stimulation in control but dropped in mutant (Fig 2A). In the long term, control mice axons were able to maintain their lactate homeostasis while mutant mice axons could not (Fig 2A, red line).

Fig 2. Mutant mice axons display an altered metabolic response to electrical stimulations.

Fig 2

The ratio of fluorescent probes (R) was normalized over the average ratio at time points before the first stimulation (R0)(basal value). Segments at the top of each Control mice graphs show stimulation periods. Lines show the basal value line. Statistical analysis shows the test for linear trend following one-way ANOVA analysis. Error bars represent SEM. A- n = 20 axons, 7 mice for Control and 7 axons, 4 mice for Mutant. B- n = 6 axons, 3 mice for Control and 9 axons, 3 mice for Mutant. C- n = 16 axons, 5 mice for Control and 14 axons, 5 mice for Mutant.

Beside lactate, another way axons may feed their mitochondria is glucose-derived pyruvate. Thus, we used a glucose-specific probe (FLII12Pglu-700uδ6, S5B Fig in S1 File) [26] to investigate glucose level in axons in the same conditions. While in resting axons a similar amount of glucose was found in both genotypes (S6B Fig in S1 File), upon electrical stimulations glucose increased in axons of mutant mice while it remained stable in control mice (2B Fig), suggesting that axons of mutant mice mobilized glucose instead of lactate upon stimulations. We finally investigated the production of ATP by axonal mitochondria in vivo using a mitochondria-targeted fluorescent probe detecting ATP (ATeam, S5C Fig in S1 File) [27]. Again, no difference could be seen in resting conditions (S6C Fig in S1 File). However, when axons were stimulated mutant mice mitochondria failed to increase ATP production while this production increased in control mice (Fig 2C). Thus, in absence of aerobic glycolysis in mSC, lactate homeostasis and mitochondria ATP production are impaired in electrically active axons, despite the mobilization of glucose.

Behavior impairment and neuromuscular junction loss in PKM2-SCKO mice are not due to demyelination

Since we observed a deficit in energy production in axons, we tested whether this had an impact on motor capacities of mutant mice. A longitudinal analysis revealed a significant deficit in mutant mice in both Rotarod and grip tests (Fig 3A, 3B), which primarily involve peripheral nerves functions, while in openfield test, which primarily involves brain functions, no defect was found (S7 Fig in S1 File). This suggested a direct influence of the metabolic changes observed in mutant mice axons on peripheral nerves functions. We next measured the nerve conduction velocity of sciatic nerves, and noticed it was not altered in mutant mice (Fig 3C) indicating that the myelin sheath was not affected. Accordingly, electron microscopy analyses showed correctly myelinated axons with a slightly increased g-ratio in mutant mice (S8A and S8B Fig in S1 File). Axonal diameter distribution was also slightly shifted toward larger axons in Mutant vs Control animals (S8C Fig in S1 File). As larger axons display a higher g-ration (S8A Fig in S1 File), this change may explain the g-ratio increase. However, the conduction of action potentials along myelinated axons was not altered as the electrophysiological properties of sciatic nerve axons ex vivo were maintained even at very high firing frequencies (S9 Fig in S1 File, S1 Table). Motor neuron number did not change in the spinal cord (Fig 3D) but they displayed a higher expression of cleaved Caspase 3 (Fig 3E and S9 Fig in S1 File), a marker of neuronal stress and axonal degeneration [34]. Indeed, tracking axonal mitochondria in vivo revealed a decrease of their movements in mutant mice both before and after electrical stimulation (Fig 3F). In addition, mutant mice showed significantly more denervated neuromuscular junctions with intact postsynaptic structures (Fig 3G and 3H) in the gastrocnemius muscle, suggesting the retraction of axon terminals. Taken together, these data indicated that PKM2 deletion did not affect the maintenance of the myelin sheet but resulted in a motor distal neuropathy in mice. This indicated that aerobic glycolysis is required in mSC for the maintenance of axonal trafficking and neuromuscular junctions.

Fig 3. Mutant mice show motor deficit and display axonal defects.

Fig 3

A- Rotarod latency to fall and B- grip strength were measured between 2 and 16 months postnatal on Control (n = 21) and Mutant (n = 25) mice. Two-way non repeated measures ANOVA Sidak’s post-hoc tests. C- Nerve conduction velocity (NCV) measured in Control and Mutant mice (n = 10 each). Two-way non repeated measures ANOVA Sidak’s post-hoc tests. D- Spinal cord sections of Mutant (Mut) and Control (Cont) mice (12 months) were stained with cresyl violet and motor neurons were counted (see S8 Fig in S1 File). n = 3 animals (14 to 30 sections). Two tailed Student t-test. E- Spinal cord sections of Mutant (Mut, n = 19 images, 3 animals) and Control (Cont, n = 12 images, 2 animals) mice were immunostained for Caspase 3, ChAT and Neurofilament (S8 Fig in S1 File) (12 months old). Caspase 3 positive neurons in percentage of Neurofilament positive neurons. Two tailed Student t-test. F- Axonal mitochondria labelled with mito-Dsred2 were imaged in vivo before and after electrical stimulation. Upper panels show typical kymographs. Tracked mitochondria are shown with colour dots. Mutant mice mitochondria follow a straight pattern indicating they are immobile or slowly moving. Lower panel: Mitochondria speed was plotted according to the genotype before and after stimulation. One-way ANOVA Tukey’s post-hoc test. n are provided in Material and Methods. G- Gastrocnemius muscle neuromuscular junctions of 12 months old Mutant and Control mice were stained for presynaptic SV2 and postsynaptic acetylcholine receptor with FITC-α-bungarotoxin (α-bung). Scale bar = 100μm. H- Innervated (inn, complete overlap), partially innervated (part, partial overlap) and denervated (den, no overlap) junctions were counted on sections as shown in D. Two tailed Student t-test. n = 4 mice (12 months). Error bars represent SEM.

Long-term maintenance of axons function relies on lactate feeding by SC

To investigate further the role of lactate intake in axons’ long term maintenance, we treated mutant and control mice with dichloroacetate (DCA), a drug that promotes mitochondrial consumption of pyruvate and decreases the availability of lactate (Fig 4A) [20]. DCA treatment has been considered for patients suffering from congenital lactic acidosis and for cancer treatment but it can lead to a reversible peripheral neuropathy primarily affecting axons in humans and rodents [18]. Over the seven weeks of treatment, the chosen dose (500mg/kg daily) was not sufficient to induce the significant reduction of nerve conduction velocity (Fig 4C) reported previously at 1g/kg [35]. Nevertheless, Rotarod performance decreased in treated mice independently of the genotype (Fig 4B), suggesting an axonal defect. When the treatment stopped, control mice recovered over 3 weeks on the Rotarod while mutant mice did not (Fig 4B). This indicated that axonal function was definitely damaged in these mice, confirming that aerobic glycolysis is required in mSC for the long-term maintenance of peripheral axons’ physiology.

Fig 4. PKM2 deletion in mSC impairs motor performance recovery after DCA treatment.

Fig 4

A- Metabolic pathways directly affected by the manipulations. LDH: lactate dehydrogenase; PDH: pyruvate dehydrogenase; PDK: PDH kinase. B- Rotarod latency to fall was measured in 9 months old Control (n = 5) and Mutant mice (n = 5) during a 7 weeks daily treatment with DCA and then during a three weeks recovery period without treatment. Two-way non repeated measures ANOVA Sidak’s post-hoc test from week 7 to week 10. C- Nerve conduction velocity (NCV) measured in 9 months old Control (n = 5) and Mutant mice (n = 7) at 0, 3 and 7 weeks of DCA treatment and 3 weeks after stopping the treatment (week 10). Two-way non repeated measures ANOVA statistical tests, Sidak’s post-hoc tests over the 4 time points. Error bars represent SEM.

Discussion

While the role of the lactate in the metabolic crosstalk between axons and the surrounding glia has been recognized for a long time in the CNS [1], its role remains unclear in the PNS. The presence of lactate in peripheral nerves had been detected and ex vivo experiments had shown that it could support action potentials propagation along axons [36]. However, the cellular origin of the released lactate and its relevance as an energy substrate for axons remains largely unclear [37]. By deleting PKM2 in mSC in vivo we showed that part of this nerve lactate is provided by mSC using aerobic glycolysis and this lactate is required for axons to maintain their metabolic homeostasis and functions over time.

CNS lactate and functions required for open field test were not affected by PKM2 deletion in myelin-forming cells. It remains possible that other CNS functions not involved in open field test are affected by PKM2 deletion and additional tests should be performed to investigate this. However, it is important to note here that CNS neurons are directly surrounded by at least two types of glial cells, astrocytes and oligodendrocytes, which are both able to shuttle lactate into neurons [68]. Thus, deleting PKM2 in only one of these glial cell types may not be sufficient to decrease brain lactate or to impair neuronal function.

Lactate is abundant in the body and in particular in the nervous system but axons appear unable to use this lactate to maintain their homeostasis. In these conditions, rescuing the phenotype of mutant mice through a supplementation in lactate appeared useless. However, allowing SC to produce more lactate despite the loss of PKM2 or specifically increasing lactate uptake by axons may represent a relevant but challenging strategy to rescue this phenotype.

Unexpectedly, and to the opposite of cancer cells, preventing mSC performing aerobic glycolysis had very little impact on its own physiology and biology. Indeed, no major defect could be detected in the myelin sheath of PKM2 mutant mice and the nerve conduction was not affected. A slight but significant shift occurred in the amount of some acylcarnitines without any alteration of the carnitine/acylcarnitine ratio, suggesting a higher turnover of these compounds that shuttle lipids into mitochondria for β-oxidation. According to the literature, we interpreted these data as the sign of a higher metabolic activity of mSC mitochondria. This is consistent with the upregulation of PKM1 expression we observed in mutant mice nerves as the higher enzymatic activity of this isoform promotes pyruvate production and its use in the mitochondrial citric acid cycle and respiration. In the absence of PKM2, mSC metabolism probably shifted to more oxidative phosphorylation. As mSC cannot be dispensed of mitochondrial respiration [7, 9], this shift is likely to be mild for the cell which is still able to produce myelin and maintain it. However, as evidenced by our results the shutdown of aerobic glycolysis in mSC is clearly deleterious for axonal maintenance. Therefore, we conclude that mSC use simultaneously both mitochondrial respiration for myelin production and maintenance and aerobic glycolysis to support axons survival.

The challenge in the analysis of metabolic crosstalk in a tissue is to distinguish between the metabolisms of the different cell types. In addition, nerve injury or section immediately modifies both axonal and glial mitochondria physiology [38]. To overcome these challenges, we chose to use the genetically encoded fluorescent probes delivered specifically to axons or mSC in vivo to follow a few critical metabolites in real time in physiological conditions. These probes such as lactate sensor Laconic, the glucose sensor FLII12Pglu-700uδ6 and the ATP sensor ATeam have been extensively characterized in several in vitro and in vivo models and we confirmed that variations could be observed in the nerve in vivo. Although this gave us a limited view of all the metabolic changes that may have occurred in mutant cells, we could nevertheless draw some decisive conclusions.

Firstly, we observed that the metabolic homeostasis is really efficient in peripheral nerves. While electrically activated axons show radical alterations in mutant mice in just a few dozens of minutes in particular for lactate, no change could be detected in resting axons of anesthetized animals disregarding the genotype. In this regard, axonal homeostasis is much more efficient than mSC homeostasis as lactate levels remained significantly lower in these cells in mutant mice than in control mice. However, axonal homeostasis was not sufficient to buffer the metabolic changes that occur following physiological stimulations. Indeed, while axonal lactate remained apparently unaltered after stimulations in control mice, it sharply and steadily dropped in mutant mice axons. This revealed that actually the maintenance of lactate levels in control mice axons is due to a significant uptake of mSC lactate to compensate for a severe consumption during axonal activity [39]. Therefore, lactate produced by mSC is a critical fuel for mitochondria of actively-firing myelinated axons. Indeed, even the mobilization of glucose in stimulated axons was not sufficient to sustain an adequate ATP production in mitochondria. The involvement of the mSC lactate was definitively confirmed by the DCA treatment. Mutant mice were unable to recover their performances on the Rotarod following the draining of lactate supplies, while mice that could produce lactate in their mSC through aerobic glycolysis recovered. This underlines the dependence of myelinated axons to mSC lactate as all the other sources of energy substrates such as glucose, glycogen or glutamine are not directly altered by DCA. The reason for this dependence is puzzling but one possibility could be the swift accessibility of this glial lactate pool and its readiness for mitochondrial respiration while using glucose may require more time and enzymatic resources in the axons to generate pyruvate. This concept is supported by the recent discovery of a transient upregulation of glycolysis in mSC and the involvement of MCT to promote axons survival in an peripheral nerve injury model [40].

As we did not investigate the sensory function of peripheral nerves, the main macroscopic phenotype that we detected is a motor weakness observed through Rotarod and grip test in the absence of demyelination. This was not significantly detectable before 6 months suggesting a late onset of the distal motor neuropathy. Taken together, this is characteristic of axonal Charcot-Marie-Tooth diseases in mice. Moreover, this neuropathy did not result from motor neurons death but from an axonal dysfunction illustrated by a decreased mitochondrial motility and retracted neuromuscular terminals. This retraction is likely to be the main cause of the motor weakness. Mitochondrial migration, which is essential for the maintenance of the synapses, in particular in motor neurons [41], relies on the ATP produced in mitochondria. In a previous work we showed that shutting down ATP synthase activity steadily slowed down mitochondrial movements in mSC in vivo [42]. Taken together, our results suggest that, the failure of mutant mice axonal mitochondria to increase their ATP production following physiological activity is the likely initial cause of the axonal dysfunction.

However, axonal firing properties were not significantly altered by this mitochondrial failure. This was unexpected because a largely accepted idea is that axonal ATP, and therefore axonal mitochondria, are required to maintain the membrane negative potential that allows depolarization. Actually, more recent analysis of neuronal energetics indicates that the energy cost of maintaining axon membrane potential is not that important, especially in myelinated fibers [1]. Therefore, the production of ATP by mutant mice axonal mitochondria may be sufficient to support this cost. Nevertheless, our data clearly indicate that mitochondrial ATP production and adaptation to the axon activity is critical for axonal maintenance.

Matching the energy demand of axons is critical to ensure the long-term maintenance of the nervous system. Indeed, increasing evidences indicate that an unbalanced energy supply to axons is a capital factor of neurodegenerative diseases such as ALS [43], Parkinson and Alzheimer diseases [44] or leprosis Mycobacterium Leprae-induced peripheral neuropathy [45]. However, the molecular basis of this support remains unclear. The present data show that axonal dysfunction may be a direct result of perturbed metabolic support by glial cells such as mSC. In this regard, the effect of DCA treatment on control and mutant mice motor performances is striking and the inability of mutant mice to recover from this treatment is challenging. Indeed, DCA is proposed as a long-term treatment for several cancers and other diseases such as acute and chronic lactic acidosis and diabetes. Our data suggest that drugs targeting aerobic glycolysis metabolism as a treatment for these diseases may have a singular and deleterious effect on the peripheral nervous system. Therefore, further and finer characterization of the axon/glia metabolic crosstalk is required in particular in neurodegenerative diseases.

Supporting information

S1 File

(DOCX)

S1 Table. Electrophysiological characteristics of control and mutant mice.

(DOCX)

S1 Data

(XLSX)

S1 Raw images

(PDF)

Acknowledgments

We thank H.Boukhaddaoui, C.Sar, V.Baecker and the imaging facility MRI, the INM animal facility, L.Diouloufet and C. Cazevieille.

Data Availability

All relevant data are within the manuscript and its Supporting Information files (supplementary information and raw data files).

Funding Statement

European Research Council grant (FP7-IDEAS-ERC #311610), INSERM AVENIR, EpiGenMed Labex, The Neuromuscular Research Association Basel, Swedish StratNeuro program, Swedish Research Council grant (#2015-02394), and AFM-Téléthon (#20044).

References

  • 1.Harris JJ, Attwell D. The energetics of central nervous system white matter. J Neurosci. 2012;32: 356–371. doi: 10.1523/JNEUROSCI.3430-11.2012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Attwell D, Laughlin SB. An Energy Budget for Signaling in the Grey Matter of the Brain. J Cereb Blood Flow Metab. 2001;21: 1133–1145. doi: 10.1097/00004647-200110000-00001 [DOI] [PubMed] [Google Scholar]
  • 3.Alle H, Roth A, Geiger JRP. Energy-Efficient Action Potentials in Hippocampal Mossy Fibers. Science. 2009;325: 1405–1408. doi: 10.1126/science.1174331 [DOI] [PubMed] [Google Scholar]
  • 4.Waxman SG. Axon-glia interactions: building a smart nerve fiber. Curr Biol. 1997;7: R406–410. doi: 10.1016/s0960-9822(06)00203-x [DOI] [PubMed] [Google Scholar]
  • 5.Waxman SG. Determinants of conduction velocity in myelinated nerve fibers. Muscle Nerve. 1980;3: 141–150. doi: 10.1002/mus.880030207 [DOI] [PubMed] [Google Scholar]
  • 6.Magistretti PJ, Allaman I. A Cellular Perspective on Brain Energy Metabolism and Functional Imaging. Neuron. 2015;86: 883–901. doi: 10.1016/j.neuron.2015.03.035 [DOI] [PubMed] [Google Scholar]
  • 7.Funfschilling U, Supplie LM, Mahad D, Boretius S, Saab AS, Edgar J, et al. Glycolytic oligodendrocytes maintain myelin and long-term axonal integrity. Nature. 2012;485: 517–521. doi: 10.1038/nature11007 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Lee Y, Morrison BM, Li Y, Lengacher S, Farah MH, Hoffman PN, et al. Oligodendroglia metabolically support axons and contribute to neurodegeneration. Nature. 2012;487: 443–448. doi: 10.1038/nature11314 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Della-Flora Nunes G, Mueller L, Silvestri N, Patel MS, Wrabetz L, Feltri ML, et al. Acetyl-CoA production from pyruvate is not necessary for preservation of myelin. Glia. 2017;65: 1626–1639. doi: 10.1002/glia.23184 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Bouçanova F, Pollmeier G, Sandor K, Urbina CM, Nijssen J, Médard J-J, et al. Disrupted function of lactate transporter MCT1, but not MCT4, in Schwann cells affects the maintenance of motor end-plate innervation. Glia. 2021;69: 124–136. doi: 10.1002/glia.23889 [DOI] [PubMed] [Google Scholar]
  • 11.Jha MK, Morrison BM. Lactate Transporters Mediate Glia-Neuron Metabolic Crosstalk in Homeostasis and Disease. Front Cell Neurosci. 2020;14. doi: 10.3389/fncel.2020.589582 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Philips T, Mironova YA, Jouroukhin Y, Chew J, Vidensky S, Farah MH, et al. MCT1 Deletion in Oligodendrocyte Lineage Cells Causes Late-Onset Hypomyelination and Axonal Degeneration. Cell Reports. 2021;34: 108610. doi: 10.1016/j.celrep.2020.108610 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 13.Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324: 1029–1033. doi: 10.1126/science.1160809 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Israelsen WJ, Dayton TL, Davidson SM, Fiske BP, Hosios AM, Bellinger G, et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells. Cell. 2013;155: 397–409. doi: 10.1016/j.cell.2013.09.025 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.He X, Du S, Lei T, Li X, Liu Y, Wang H, et al. PKM2 in carcinogenesis and oncotherapy. Oncotarget. 2017;8: 110656–110670. doi: 10.18632/oncotarget.22529 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Hanahan D, Weinberg RA. Hallmarks of Cancer: The Next Generation. Cell. 2011;144: 646–674. doi: 10.1016/j.cell.2011.02.013 [DOI] [PubMed] [Google Scholar]
  • 17.Frezza C, Gottlieb E. Mitochondria in cancer: Not just innocent bystanders. Seminars in Cancer Biology. 2009;19: 4–11. doi: 10.1016/j.semcancer.2008.11.008 [DOI] [PubMed] [Google Scholar]
  • 18.James MO, Stacpoole PW. Pharmacogenetic considerations with dichloroacetate dosing. Pharmacogenomics. 2016;17: 743–753. doi: 10.2217/pgs-2015-0012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Tataranni T, Piccoli C. Dichloroacetate (DCA) and Cancer: An Overview towards Clinical Applications. In: Oxidative Medicine and Cellular Longevity [Internet]. 2019. [cited 5 Mar 2020]. 10.1155/2019/8201079 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Stacpoole PW. The pharmacology of dichloroacetate. Metabolism. 1989;38: 1124–1144. doi: 10.1016/0026-0495(89)90051-6 [DOI] [PubMed] [Google Scholar]
  • 21.James MO, Jahn SC, Zhong G, Smeltz MG, Hu Z, Stacpoole PW. Therapeutic applications of dichloroacetate and the role of glutathione transferase zeta-1. Pharmacology & Therapeutics. 2017;170: 166–180. doi: 10.1016/j.pharmthera.2016.10.018 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Doerflinger NH, Macklin WB, Popko B. Inducible site-specific recombination in myelinating cells. Genesis. 2003;35: 63–72. doi: 10.1002/gene.10154 [DOI] [PubMed] [Google Scholar]
  • 23.Dray S, Dufour A-B. The ade4 Package: Implementing the Duality Diagram for Ecologists. Journal of Statistical Software. 2007;22: 1–20. [Google Scholar]
  • 24.Clower CV, Chatterjee D, Wang Z, Cantley LC, Vander Heiden MG, Krainer AR. The alternative splicing repressors hnRNP A1/A2 and PTB influence pyruvate kinase isoform expression and cell metabolism. Proc Natl Acad Sci U S A. 2010;107: 1894–1899. doi: 10.1073/pnas.0914845107 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.San Martín A, Ceballo S, Ruminot I, Lerchundi R, Frommer WB, Barros LF. A genetically encoded FRET lactate sensor and its use to detect the Warburg effect in single cancer cells. PLoS ONE. 2013;8: e57712. doi: 10.1371/journal.pone.0057712 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Takanaga H, Chaudhuri B, Frommer WB. GLUT1 and GLUT9 as major contributors to glucose influx in HepG2 cells identified by a high sensitivity intramolecular FRET glucose sensor. Biochim Biophys Acta. 2008;1778: 1091–1099. doi: 10.1016/j.bbamem.2007.11.015 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Tsuyama T, Kishikawa J, Han Y-W, Harada Y, Tsubouchi A, Noji H, et al. In vivo fluorescent adenosine 5’-triphosphate (ATP) imaging of Drosophila melanogaster and Caenorhabditis elegans by using a genetically encoded fluorescent ATP biosensor optimized for low temperatures. Anal Chem. 2013;85: 7889–7896. doi: 10.1021/ac4015325 [DOI] [PubMed] [Google Scholar]
  • 28.Sajic M, Mastrolia V, Lee CY, Trigo D, Sadeghian M, Mosley AJ, et al. Impulse Conduction Increases Mitochondrial Transport in Adult Mammalian Peripheral Nerves In Vivo. PLoS Biol. 2013;11. doi: 10.1371/journal.pbio.1001754 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Tricaud N, Perrin-Tricaud C, Brusés JL, Rutishauser U. Adherens Junctions in Myelinating Schwann Cells Stabilize Schmidt-Lanterman Incisures via Recruitment of p120 Catenin to E-Cadherin. J Neurosci. 2005;25: 3259. doi: 10.1523/JNEUROSCI.5168-04.2005 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30.Gonzalez S, Fernando RN, Perrin-Tricaud C, Tricaud N. In vivo introduction of transgenes into mouse sciatic nerve cells in situ using viral vectors. Nature Protocols. 2014;9: 1160–1169. doi: 10.1038/nprot.2014.073 [DOI] [PubMed] [Google Scholar]
  • 31.Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O’Keeffe S, et al. An RNA-Sequencing Transcriptome and Splicing Database of Glia, Neurons, and Vascular Cells of the Cerebral Cortex. J Neurosci. 2014;34: 11929–11947. doi: 10.1523/JNEUROSCI.1860-14.2014 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Indiveri C, Iacobazzi V, Tonazzi A, Giangregorio N, Infantino V, Convertini P, et al. The mitochondrial carnitine/acylcarnitine carrier: Function, structure and physiopathology. Molecular Aspects of Medicine. 2011;32: 223–233. doi: 10.1016/j.mam.2011.10.008 [DOI] [PubMed] [Google Scholar]
  • 33.Viader A, Sasaki Y, Kim S, Strickland A, Workman CS, Yang K, et al. Aberrant Schwann cell lipid metabolism linked to mitochondrial deficits leads to axon degeneration and neuropathy. Neuron. 2013;77: 886–898. doi: 10.1016/j.neuron.2013.01.012 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Mukherjee A, Williams DW. More alive than dead: non-apoptotic roles for caspases in neuronal development, plasticity and disease. Cell Death Differ. 2017;24: 1411–1421. doi: 10.1038/cdd.2017.64 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Stacpoole PW, Martyniuk CJ, James MO, Calcutt NA. Chapter Eight—Dichloroacetate-induced peripheral neuropathy. In: Fernyhough P, Calcutt NA, editors. International Review of Neurobiology. Academic Press; 2019. pp. 211–238. doi: 10.1016/bs.irn.2019.05.003 [DOI] [PubMed] [Google Scholar]
  • 36.Brown AM, Evans RD, Black J, Ransom BR. Schwann Cell Glycogen Selectively Supports Myelinated Axon Function. Ann Neurol. 2012;72: 406–418. doi: 10.1002/ana.23607 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Stassart RM, Möbius W, Nave K-A, Edgar JM. The Axon-Myelin Unit in Development and Degenerative Disease. Front Neurosci. 2018;12: 467. doi: 10.3389/fnins.2018.00467 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38.Kerschensteiner M, Schwab ME, Lichtman JW, Misgeld T. In vivo imaging of axonal degeneration and regeneration in the injured spinal cord. Nat Med. 2005;11: 572–577. doi: 10.1038/nm1229 [DOI] [PubMed] [Google Scholar]
  • 39.Rich LR, Brown AM. Fibre sub-type specific conduction reveals metabolic function in mouse sciatic nerve: Simultaneous recording of sciatic nerve A and C fibre CAPs. J Physiol. 2018;596: 1795–1812. doi: 10.1113/JP275680 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Babetto E, Wong KM, Beirowski B. A glycolytic shift in Schwann cells supports injured axons. Nature Neuroscience. 2020;23: 1215–1228. doi: 10.1038/s41593-020-0689-4 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Marinković P, Reuter MS, Brill MS, Godinho L, Kerschensteiner M, Misgeld T. Axonal transport deficits and degeneration can evolve independently in mouse models of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012;109: 4296–4301. doi: 10.1073/pnas.1200658109 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Gonzalez S, Fernando R, Berthelot J, Perrin-Tricaud C, Sarzi E, Chrast R, et al. In vivo time-lapse imaging of mitochondria in healthy and diseased peripheral myelin sheath. Mitochondrion. 2015;23: 32–41. doi: 10.1016/j.mito.2015.05.004 [DOI] [PubMed] [Google Scholar]
  • 43.Vandoorne T, De Bock K, Van Den Bosch L. Energy metabolism in ALS: an underappreciated opportunity? Acta Neuropathol. 2018;135: 489–509. doi: 10.1007/s00401-018-1835-x [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Camandola S, Mattson MP. Brain metabolism in health, aging, and neurodegeneration. EMBO J. 2017;36: 1474–1492. doi: 10.15252/embj.201695810 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Medeiros RCA, Girardi K do C de V, Cardoso FKL, Mietto B de S, Pinto TG de T, Gomez LS, et al. Subversion of Schwann Cell Glucose Metabolism by Mycobacterium leprae. J Biol Chem. 2016;291: 21375–21387. doi: 10.1074/jbc.M116.725283 [DOI] [PMC free article] [PubMed] [Google Scholar]

Decision Letter 0

David J Schulz

12 Feb 2022

PONE-D-21-39340Physiology of PNS axons relies on glycolytic metabolism in myelinating Schwann cellsPLOS ONE

Dear Dr. Tricaud,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

This is indeed an interesting line of investigation, and one that will likely be well received to the general readership, especially those who focus on peripheral neuropathy and axon-glia interactions. However, the reviewers have some concerns that should be addressed.

In particular, all reviewers raise points related to how the data may be insufficient to fully warrant the conclusions drawn in the Discussion. Each of the reviewers has suggestions for how the Discussion and interpretation may need to be considered based on potential discrepancies in the results and the conclusions presented. Having seen the reviewers' comments, should the authors feel they can address these concerns in revision they are strongly encouraged to do so. However, if additional experiments (Rev 1: rescue with lactate administration) or inclusion of additional data (e.g. Rev 2: mean axon diameter in control vs. mutant) such has those suggested by the reviewers are feasible, they would certainly strengthen the study and its conclusions.

Finally, please be sure to look at the checklists that each reviewer has provided, and address any concerns raised there. Each reviewer has provided valuable feedback, both major and minor concerns, that will undoubtedly improve the final product.

Please submit your revised manuscript by Mar 25 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

David J Schulz

Academic Editor

PLOS ONE

Journal Requirements:

1. When submitting your revision, we need you to address these additional requirements.

Please ensure that your manuscript meets PLOS ONE's style requirements, including those for file naming. The PLOS ONE style templates can be found at 

https://journals.plos.org/plosone/s/file?id=wjVg/PLOSOne_formatting_sample_main_body.pdf and 

https://journals.plos.org/plosone/s/file?id=ba62/PLOSOne_formatting_sample_title_authors_affiliations.pdf

2. Please update your submission to use the PLOS LaTeX template. The template and more information on our requirements for LaTeX submissions can be found at http://journals.plos.org/plosone/s/latex.

3. We noted in your submission details that a portion of your manuscript may have been presented or published elsewhere. (This manuscript was previously submitted to a different PLOS journal as either a presubmission inquiry or a full submission.

PLOS Biology PBIOLOGY-D-21-00914) 

Please clarify whether this [conference proceeding or publication] was peer-reviewed and formally published. If this work was previously peer-reviewed and published, in the cover letter please provide the reason that this work does not constitute dual publication and should be included in the current manuscript.

4. PLOS ONE now requires that authors provide the original uncropped and unadjusted images underlying all blot or gel results reported in a submission’s figures or Supporting Information files. This policy and the journal’s other requirements for blot/gel reporting and figure preparation are described in detail at https://journals.plos.org/plosone/s/figures#loc-blot-and-gel-reporting-requirements and https://journals.plos.org/plosone/s/figures#loc-preparing-figures-from-image-files. When you submit your revised manuscript, please ensure that your figures adhere fully to these guidelines and provide the original underlying images for all blot or gel data reported in your submission. See the following link for instructions on providing the original image data: https://journals.plos.org/plosone/s/figures#loc-original-images-for-blots-and-gels. 

  

In your cover letter, please note whether your blot/gel image data are in Supporting Information or posted at a public data repository, provide the repository URL if relevant, and provide specific details as to which raw blot/gel images, if any, are not available. Email us at plosone@plos.org if you have any questions.

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Partly

Reviewer #2: Partly

Reviewer #3: Partly

**********

2. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: I Don't Know

**********

3. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

4. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The goal of this study was to investigate the importance of lactate produced by PKM2 in myelinating Schwann cells (mSC) in peripheral axons and myelinating Schwann cells. The highlight of this study was that it showed that aerobic glycolysis may be more important for the maintenance of axonal function than myelination. The evidence for the importance of aerobic glycolysis for axonal maintenance was that the loss of PKM2 only led to deficits in axonal function and not myelin deficits. I believe the authors’ interpretation of their findings was justified with relevant experiments accompanied by proper controls. The findings are interesting, and the thorough approaches were used to reveal the role of aerobic glycolysis in maintaining neuronal function via mSC. The authors also highlight the translational relevance of their findings to neurodegenerative diseases where axonal energy imbalance is a key feature. They also suggest that caution should be taken when treating patients with drugs that target aerobic glycolysis as these drugs could damage the peripheral nervous system.

The strengths of study include:

1) Characterizing the localization of PKM1 and 2 during early postnatal development was strong evidence that gave insights into the functional divergence between the PKM1 and PKM2.

2) There was good validation of the effectiveness of mouse PLP-PKM2 KO mouse model as various molecular techniques showed the downregulation of PKM2. There was also good proof of principle that reduction in PKM2 reduced lactate in mSC.

3) The use of specific probes for aerobic glycolytic substrates/ products allowed direct quantification in the changes of these substrates with the loss of PKM2

However, there are a few concerns need to be addressed by the authors before the work can be published.

Major concerns:

1) PLP1 is not only expressed in myelinating Schwann cells, but also in myelinating oligodendrocytes in the CNS. Additionally, the authors didn’t address whether PKM2 is mostly expressed in the PNS or has more relevance to the PNS. Therefore, the behavioral changes in the mice could also be a result of dysfunction in the CNS.

2) There were no rescue experiments presented. If the authors believe that reduction of lactate is the main reason causing neuronal dysfunction. Instead of further inhibiting lactate production with DCA treatment, they should supply the lactate to the animals and see whether that could rescue the phenotypes, because PMK2 KO could lead to many other defects (i.e. mitochondrial defects) reducing besides lactate production.

Minor Issues:

1) The RT-PCR results from figure 1D does not reflect protein expression level of figure 1C. Would be helpful to normalize the immunoblot data from 1C to help with the variation in the control.

2) There are several grammatical errors throughout the paper for example lines 51, 77, and 115.

3) In the abstract, it is said that PKM2 is upregulated in mSC, however, no comparison is given i.e. what condition is the upregulation compared to?

4) The authors mention abbreviations such as TFAM1 and CMT but these were never introduced to the reader.

5) It was not mentioned whether the electrical stimulations are physiologically relevant/ significant.

6) The authors need to justify why a PLP-cre mice was used instead of a PNS specific mouse model such as MPZ-cre.

7) In the summary it would be a good idea to explain briefly to the readers what the lactate shuttle theory is instead of assuming they know it. This will give the reader a better initial understanding as they begin to read the paper i.e. improve the readability.

8) In the summary, it would also be good to state that aerobic lactate production by PKM2 is important for neuron/ glia cells just as how the authors stated it is important for cancer.

9) The study is focused on mSC, the authors need to clearly state whether this focus is mainly because maintaining metabolic homeostasis is more important for neurons with long axons.

Reviewer #2: Deck and colleagues present a phenotyping of peripheral nerve structure and function in a mouse model of conditional pyruvate kinase M2 (PKM2) deletion ± superimposition of treatment with dichloroacetate (DCA). Despite expression of PKM2 in adult nerve being focused on Schwann cells, the authors build an argument that impaired lactate transfer to axons in PKM2 mutant mice results in a distal degenerative axonopathy.

The studies are novel, potentially important to understanding both basic neurobiology and the pathogenesis of peripheral neuropathies and use state of the art techniques. Comments:

1. Phenotyping of neuropathy is limited and lacks a number of widely used assessments that are standard for the field in rats or mice. The absence of behavioral, functional and structural assays for large and small sensory fibers is particularly troubling, given that sensory dysfunction is a common feature of many peripheral neuropathies and that large and small fiber sensory disorders are reported in the PNS of rats with DCA-induced neuropathy (see work by Stacpoole and colleagues, JNEN 2009).

2. The lack of MNCV slowing in DCA treated mice (Fig 4) is inconsistent with prior reports in rats (see above mentioned paper) and mice (Stacpoole et al Int. Rev. Neurobiol. 2019). This discrepancy should be discussed.

3. The focus on motor neuropathy in the discussion is also not consistent with the data generated. While some measures of motor neuropathy are reported (grip strength, loss of NMJ), characterization of PKM1/PKM2 expression is performed in the sciatic nerve, so does not distinguish between large motor and sensory fibers, while a number of other experiments, such as the studies of lactate and ATP homeostasis (Fig 2, Fig S5) are performed in saphenous nerve, a sensory nerve.

4. Given that the authors have pretty good EM images and have calculated G-ratio and axonal diameter, it would be very helpful to know if mean axonal diameter was different between the control and mutant mice (Fig S6), as this value is reduced in the sural (sensory) and tibial (mixed) nerves of rats with DCA neuropathy (see above mentioned paper). A plot of the size: frequency distributions for both groups would suffice.

5. References need to be provided in English (months are in French).

Some of the above can be addressed using images available to the authors. However, as written, the discussion is not entirely consistent with the data and develops a motor neuropathy focused agenda that, in the absence of sensory phenotyping, is unwarranted. Without requiring additional studies in new colonies of mice, the discussion should be revised to a) clearly identify data produced in motor vs sensory vs mixed nerves, b) de-emphasize the focus on motor neuropathy and c) acknowledge deficiencies in phenotyping that have excluded measures of sensory neuropathy.

Reviewer #3: Deck et al demonstrate that PKM2 is upregulated in myelinating Schwann cells (mSC) and deleting PKM2 in mice (through PLP expressing cells) (Schwann cells in the PNS) leads to reduced lactate in mSC and an axonal neuropathy in mice. The authors conclude that lactate production through aerobic glycolysis is necessary in mSC for the maintenance of axonal physiology in the PNS. The authors cite literature from the CNS in which astrocytes and oligodendrocytes metabolize glucose into lactate via the “lactate shuttle”. Depletion of PKM2 led to a deficit in Rotarod and grip strength. However ,nerve conducitons, CMAP amplitudes, and g-ratios morphologically were not changed. Mitochondrial movements were reduced and neuromuscular junctions appeared increasingly denervated. Treating mice with dicholoroacetate (DCA), which increases mitochondrial consumption of pyruvate and decreases lactate availability, exacerbated Rotarod dysfunction but did not affect the NCV. The authors surmise that DCA, a potential treatment for cancers and diabetes may constitute a risk for peripheral nerve function in patients.

The manuscript was well done and the biology is interesting. However there is concern about the significance of the abnormalities caused by knocking down PKM@. Chaanges in Rotaarod and grip without changes in neurophysiology or overall morphology (normal g-ratios) are always concerning. The data on partially innervated or denervated neuromuscular junctions is not convincing. The magnification is difficult to interpret on the immunohistochemistry. The gastrocnemius is a difficult muscle to quantitate NMJ changes on.

Finally raising a potential clinical concern for patients based on these abnormalities is probably not warrented

**********

6. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Reviewer #3: No

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Oct 4;17(10):e0272097. doi: 10.1371/journal.pone.0272097.r002

Author response to Decision Letter 0


8 Jun 2022

Reviewer #1: The goal of this study was to investigate the importance of lactate produced by PKM2 in myelinating Schwann cells (mSC) in peripheral axons and myelinating Schwann cells. The highlight of this study was that it showed that aerobic glycolysis may be more important for the maintenance of axonal function than myelination. The evidence for the importance of aerobic glycolysis for axonal maintenance was that the loss of PKM2 only led to deficits in axonal function and not myelin deficits. I believe the authors’ interpretation of their findings was justified with relevant experiments accompanied by proper controls. The findings are interesting, and the thorough approaches were used to reveal the role of aerobic glycolysis in maintaining neuronal function via mSC. The authors also highlight the translational relevance of their findings to neurodegenerative diseases where axonal energy imbalance is a key feature. They also suggest that caution should be taken when treating patients with drugs that target aerobic glycolysis as these drugs could damage the peripheral nervous system.

The strengths of study include:

1) Characterizing the localization of PKM1 and 2 during early postnatal development was strong evidence that gave insights into the functional divergence between the PKM1 and PKM2.

2) There was good validation of the effectiveness of mouse PLP-PKM2 KO mouse model as various molecular techniques showed the downregulation of PKM2. There was also good proof of principle that reduction in PKM2 reduced lactate in mSC.

3) The use of specific probes for aerobic glycolytic substrates/ products allowed direct quantification in the changes of these substrates with the loss of PKM2

However, there are a few concerns need to be addressed by the authors before the work can be published.

Major concerns:

1) PLP1 is not only expressed in myelinating Schwann cells, but also in myelinating oligodendrocytes in the CNS. Additionally, the authors didn’t address whether PKM2 is mostly expressed in the PNS or has more relevance to the PNS. Therefore, the behavioral changes in the mice could also be a result of dysfunction in the CNS.

PLP1 and PKM2 are indeed expressed in CNS oligodendrocytes, cells that play a role in the motor behaviour among other brain functions in mice. In another project we investigated the role of PKM2 in the CNS glia and we used PLP-ERT2-PKM2 flox mutant mice in an Open Field (OPF) experiment, a assay that typically address CNS defects. No deficiency was found in homozygous mice vs heterozygous mice using this assay (see figure below) suggesting that brain defects are absent or too mild to be detected using much simpler motor tests such as grip test and Rotarod. In addition, we did not find any decrease in lactate in the brain of mutant mice suggesting that deleting PKM2 in CNS oligodendrocytes has no impact on lactate supply to neurons.

We propose to add the lactate dosing data to the manuscript as supplementary Figure S3 (lactate dosing in mouse brain) and OPF data in Figure S7. These data are described in the manuscript page 17 and page 19 and discussed page 21 in yellow underlining.

2) There were no rescue experiments presented. If the authors believe that reduction of lactate is the main reason causing neuronal dysfunction. Instead of further inhibiting lactate production with DCA treatment, they should supply the lactate to the animals and see whether that could rescue the phenotypes, because PMK2 KO could lead to many other defects (i.e. mitochondrial defects) reducing besides lactate production.

Thank you for your comment. We agree that a rescue experiment would be a valuable addition to this project. However, based on considerations outlined below, we were unable to find an appropriate timely experiment to perform such a delicate rescue.

The nervous system and nerves are full of lactate as is the blood. Nevertheless, the decrease of lactate production by SC induced by the glia-specific loss of PKM2 resulted in axonal defects among which loss of lactate homeostasis. So, even if the nerve is still full of lactate supplied by blood, axons are not able to use this lactate to maintain their homeostasis. Adding more lactate to the blood or to the nerve is therefore highly probably not going to resolve the problem that axons of mutant mice encounter. One potential approach to eventually rescue the phenotype would be by allowing SC to produce more lactate despite the loss of PKM2 or by increasing the uptake of lactate by axons themselves. While doable, these experiments go beyond supplying lactate to animals and will rather require to genetically modify axons or SC.

We added a paragraph about this in the Discussion section (page 21).

Minor Issues:

1) The RT-PCR results from figure 1D does not reflect protein expression level of figure 1C. Would be helpful to normalize the immunoblot data from 1C to help with the variation in the control.

We have quantified our WB data and plotted them as seen below. PKM2/Actin and PKM1/Actin ratio significantly decreases and increases respectively accordingly to mRNA data. These data will be available in the “Raw data file” at the tab of Figure 1C.

T-test Pvalue = 0.02

T-test Pvalue= 0.12

2) There are several grammatical errors throughout the paper for example lines 51, 77, and 115.

We thank the reviewer for this insightful review and we corrected these spelling errors.

3) In the abstract, it is said that PKM2 is upregulated in mSC, however, no comparison is given i.e. what condition is the upregulation compared to?

Thank you for your comment. We modified the abstract as following “We show here that PKM2 is also upregulated in myelinating Schwann cells (mSC) of mature mouse sciatic nerve versus postnatal immature nerve.”

4) The authors mention abbreviations such as TFAM1 and CMT but these were never introduced to the reader.

We improved the manuscript introducing these acronyms when they appear in the text.

5) It was not mentioned whether the electrical stimulations are physiologically relevant/ significant.

We confirm that they were physiologically relevant, which we added in the Results section on page 18.

6) The authors need to justify why a PLP-cre mice was used instead of a PNS specific mouse model such as MPZ-cre.

“Plp1-creERT mouse line was chosen because it is the only commercially available line allowing selective and inducible recombination in myelinating Schwann cells.” was added to the Material and methods section.

7) In the summary it would be a good idea to explain briefly to the readers what the lactate shuttle theory is instead of assuming they know it. This will give the reader a better initial understanding as they begin to read the paper i.e. improve the readability.

We modified the last sentence of the summary as following “While lactate shuttle theory states that glial cells metabolize glucose into lactate to shuttle it to neurons, how glial cells support axonal metabolism and function remains unclear.”

8) In the summary, it would also be good to state that aerobic lactate production by PKM2 is important for neuron/ glia cells just as how the authors stated it is important for cancer.

We modified the last sentence of the summary as following “Thus, lactate production through PKM2 enzyme and aerobic glycolysis is essential in mSC for the long-term maintenance of peripheral nerve axon physiology and function.”

9) The study is focused on mSC, the authors need to clearly state whether this focus is mainly because maintaining metabolic homeostasis is more important for neurons with long axons.

In our first paragraph of the introduction we outlined the reason of our focus on peripheral axons and SC: “Energetic metabolism is an essential parameter of neurons’ function and survival (1–3). Indeed, the nervous system consumes a large amount of glucose mainly to allow synapses to function but also organelles and vesicles transport along axons and action potentials firing (1). In the peripheral nervous system (PNS), axons grow far from their cell bodies to reach distant targets such as muscles. Maintaining metabolic homeostasis on such a long distance is a real challenge for peripheral nerve axons (4). To support neurons in this challenge, myelinating Schwann cells (mSC) cover the large motor axons with a myelin sheath.”

Reviewer #2: Deck and colleagues present a phenotyping of peripheral nerve structure and function in a mouse model of conditional pyruvate kinase M2 (PKM2) deletion ± superimposition of treatment with dichloroacetate (DCA). Despite expression of PKM2 in adult nerve being focused on Schwann cells, the authors build an argument that impaired lactate transfer to axons in PKM2 mutant mice results in a distal degenerative axonopathy.

The studies are novel, potentially important to understanding both basic neurobiology and the pathogenesis of peripheral neuropathies and use state of the art techniques. Comments:

1. Phenotyping of neuropathy is limited and lacks a number of widely used assessments that are standard for the field in rats or mice. The absence of behavioral, functional and structural assays for large and small sensory fibers is particularly troubling, given that sensory dysfunction is a common feature of many peripheral neuropathies and that large and small fiber sensory disorders are reported in the PNS of rats with DCA-induced neuropathy (see work by Stacpoole and colleagues, JNEN 2009).

We agree with the reviewer that the phenotype we described in this mouse model is limited to the motor behaviour. In this regard, we performed two widely used tests to assess motor capacities of mice and rats: grip test and rotarod. As multiple sensory functions are mediated by non-myelinated fibers and as we modified myelinating SC only, we did not investigate the sensory function. A follow-up study will be necessary to investigate sensory functions in more detail.

2. The lack of MNCV slowing in DCA treated mice (Fig 4) is inconsistent with prior reports in rats (see above mentioned paper) and mice (Stacpoole et al Int. Rev. Neurobiol. 2019). This discrepancy should be discussed.

We modified the Discussion section on page 20 to expand on this discrepancy a bit further: “Over the seven weeks of treatment, the chosen dose (500mg/kg daily) was not sufficient to induce the significant reduction of nerve conduction velocity (Fig. 4C) reported previously (36,37), which suggests that nerve conduction is less dependent on mSC lactate in adult rats than in juvenile rats. Despite only a minor reduction in nerve conduction, Rotarod performance decreased in treated mice independently of the genotype (Fig. 4B), suggesting an axonal defect. When the treatment stopped, control mice recovered over 3 weeks on the Rotarod while mutant mice did not (Fig. 4B).”

3. The focus on motor neuropathy in the discussion is also not consistent with the data generated. While some measures of motor neuropathy are reported (grip strength, loss of NMJ), characterization of PKM1/PKM2 expression is performed in the sciatic nerve, so does not distinguish between large motor and sensory fibers, while a number of other experiments, such as the studies of lactate and ATP homeostasis (Fig 2, Fig S5) are performed in saphenous nerve, a sensory nerve.

The goal of the study was to investigate the role of PKM2 and lactate production by glycolytic pathway in myelinating SC on the axonal function. Therefore, we discriminated myelinated fibres vs non-myelinated fibres and not motor, sensory or motor and sensory nerves. As previously explained, we initially investigate motor behaviour because all motor fibres are myelinated while only a portion of the sensory fibres is myelinated. In addition, we investigated this portion of myelinated fibres in the sensory saphenous nerve in imaging experiments. The sensory saphenous nerve was chosen for imaging experiments to avoid motor reflexes upon stimulation, which could blur images. We added this clarification in the Results section on page 18.

4. Given that the authors have pretty good EM images and have calculated G-ratio and axonal diameter, it would be very helpful to know if mean axonal diameter was different between the control and mutant mice (Fig S6), as this value is reduced in the sural (sensory) and tibial (mixed) nerves of rats with DCA neuropathy (see above mentioned paper). A plot of the size: frequency distributions for both groups would suffice.

To answer the reviewer request, we re-analyzed our semi-thin EM pictures to collect data about much more fibres in both Mutant and Control animals. These data indicated a slight but significant increase in the g-ratio of Mutant mice (Figure S8B), suggesting that myelin sheath is slightly thinner in sciatic nerves of these mice. However, no evidence of demyelination or strong dysmyelination was seen as highlighted in the results section page 19.

These new data were also plotted as frequency distribution of axonal diameter in Figure S8C as requested by the reviewer. An unpaired two-tailed Student T-test was run over these data as described in the mentioned papers and no significant change was found. This result is described and highlighted in the results section on page 19.

5. References need to be provided in English (months are in French).

We corrected this.

Some of the above can be addressed using images available to the authors. However, as written, the discussion is not entirely consistent with the data and develops a motor neuropathy focused agenda that, in the absence of sensory phenotyping, is unwarranted. Without requiring additional studies in new colonies of mice, the discussion should be revised to a) clearly identify data produced in motor vs sensory vs mixed nerves, b) de-emphasize the focus on motor neuropathy and c) acknowledge deficiencies in phenotyping that have excluded measures of sensory neuropathy.

We acknowledged in the discussion that, in absence of investigation of the sensory function, our conclusions are limited to the motor function of the nerves as highlighted at page 23.

Reviewer #3: Deck et al demonstrate that PKM2 is upregulated in myelinating Schwann cells (mSC) and deleting PKM2 in mice (through PLP expressing cells) (Schwann cells in the PNS) leads to reduced lactate in mSC and an axonal neuropathy in mice. The authors conclude that lactate production through aerobic glycolysis is necessary in mSC for the maintenance of axonal physiology in the PNS. The authors cite literature from the CNS in which astrocytes and oligodendrocytes metabolize glucose into lactate via the “lactate shuttle”. Depletion of PKM2 led to a deficit in Rotarod and grip strength. However, nerve conductions, CMAP amplitudes, and g-ratios morphologically were not changed. Mitochondrial movements were reduced and neuromuscular junctions appeared increasingly denervated. Treating mice with dicholoroacetate (DCA), which increases mitochondrial consumption of pyruvate and decreases lactate availability, exacerbated Rotarod dysfunction but did not affect the NCV. The authors surmise that DCA, a potential treatment for cancers and diabetes may constitute a risk for peripheral nerve function in patients.

The manuscript was well done and the biology is interesting. However there is concern about the significance of the abnormalities caused by knocking down PKM@. Changes in Rotaarod and grip without changes in neurophysiology or overall morphology (normal g-ratios) are always concerning.

We thank our reviewer for this comment. However, we would like to point out that hereditary peripheral neuropathies resulting from axonal dysfunction, Charcot-Marie-Tooth diseases type 2, are numerous and result in motor and sensory defects despite a normal nerve conduction velocity, normal g-ratio and limited alteration of the myelin sheath.

The data on partially innervated or denervated neuromuscular junctions is not convincing. The magnification is difficult to interpret on the immunohistochemistry. The gastrocnemius is a difficult muscle to quantitate NMJ changes on.

Although challenging, our experiments were consistent with several previous studies based on immunohistochemistry and quantification of neuromuscular junctions in the gastrocnemius, even if this muscle is thick and may not be the most amenable to look at it. A similar study was recently published in PNAS (Bernard-Marissal N, van Hameren G, Juneja M, Pellegrino C, Louhivuori L, Bartesaghi L, Rochat C, El Mansour O, Médard JJ, Croisier M, Maclachlan C, Poirot O, Uhlén P, Timmerman V, Tricaud N, Schneider BL, Chrast R. Altered interplay between endoplasmic reticulum and mitochondria in Charcot-Marie-Tooth type 2A neuropathy. Proc Natl Acad Sci U S A. 2019 Feb 5;116(6):2328-2337. doi: 10.1073/pnas.1810932116. Epub 2019 Jan 18. PMID: 30659145; PMCID: PMC6369737).

Finally raising a potential clinical concern for patients based on these abnormalities is probably not warrented

Following reviewer’s suggestion, we removed the last sentence of the discussion.

Attachment

Submitted filename: Response to Reviewers comments2.docx

Decision Letter 1

David J Schulz

6 Jul 2022

PONE-D-21-39340R1Physiology of PNS axons relies on glycolytic metabolism in myelinating Schwann cellsPLOS ONE

Dear Dr. Tricaud,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE’s publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process. All three reviewers agreed that you addressed all of their major concerns well. Reviewer 2 has a couple of minor suggestions for changes that will help make the results clearer and benefit the readership. If you could address these two points as well as you are able and resubmit, it would be appreciated. 

Please submit your revised manuscript by Aug 20 2022 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at plosone@plos.org. When you're ready to submit your revision, log on to https://www.editorialmanager.com/pone/ and select the 'Submissions Needing Revision' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

  • A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled 'Response to Reviewers'.

  • A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled 'Revised Manuscript with Track Changes'.

  • An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled 'Manuscript'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: https://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols. Additionally, PLOS ONE offers an option for publishing peer-reviewed Lab Protocol articles, which describe protocols hosted on protocols.io. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols.

We look forward to receiving your revised manuscript.

Kind regards,

David J Schulz

Academic Editor

PLOS ONE

Journal Requirements:

Please review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript. If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

[Note: HTML markup is below. Please do not edit.]

Reviewers' comments:

Reviewer's Responses to Questions

Comments to the Author

1. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the “Comments to the Author” section, enter your conflict of interest statement in the “Confidential to Editor” section, and submit your "Accept" recommendation.

Reviewer #1: All comments have been addressed

Reviewer #2: (No Response)

Reviewer #3: All comments have been addressed

**********

2. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer #1: Yes

Reviewer #2: Partly

Reviewer #3: Yes

**********

3. Has the statistical analysis been performed appropriately and rigorously?

Reviewer #1: Yes

Reviewer #2: No

Reviewer #3: Yes

**********

4. Have the authors made all data underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data—e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

5. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer #1: Yes

Reviewer #2: Yes

Reviewer #3: Yes

**********

6. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer #1: The authors have addressed all my concerns. I understand the difficulty of performing the lactate rescue experiments and including Mpz-cre.

Reviewer #2: The authors have made a good effort to address the concerns of the reviewers by amending text and adding new data and the manuscript is much improved. I have a couple of points that should be addressed.

1. In response to a request for comment on prior reports of MNCV slowing in DCA-exposed rodents the authors write “Over the seven weeks of treatment, the chosen dose (500mg/kg daily) was not sufficient to induce the significant reduction of nerve conduction velocity (Fig. 4C) reported previously (36,37), which suggests that nerve conduction is less dependent on mSC lactate in adult rats than in juvenile rats”. This interpretation is not correct as a) reference #37 reports MNCV slowing in adult DCA-exposed mice, not rats and b) reference #36 shows MNCV slowing in adult rats but not juvenile rats after exposure to 500mg/kg. DCA. The authors could simply note that their present MNCV data in adult mice exposed to 500mg/kg DCA does not replicate the prior report (ref #37) that used 1g/kg of DCA in adult mice – perhaps simply due to the lower dose used (note that 500mg/kg in rats as per reference #36 ≠ 500mg/kg in mice due absence of allometric scaling, whereas 500mg/kg in rats = 1g/kg in mice after allometric scaling).

2. The authors provide an interesting axonal size:frequency histogram (Fig S8C) and indicate that there was no difference between control and DCA exposed rats using an unpaired t test. I do not understand this analysis – what data were compared? The paper cited in the response to review used unpaired t test to compare mean axonal diameter, not the size:frequency histogram. Please report values (mean±SD) for MAD in the 2 groups to support any statistical analysis. It is also necessary to report fibers/nerve in order to fully interpret MAD or fiber size:frequency distributions, not just total number of fibers counted. Given that the size:frequency histogram (Figure S8C) suggests that DCA-exposed nerve may have a shift towards increased frequency of larger axons and reduced frequency of smaller axons, to what extent does increased axonal MAD contribute to the reported increase in g-ratio rather than the myelin thinning that the authors infer?

Reviewer #3: The authors have addressed my concerns. I have no additional concerns about the research ethics or publication ethics. This is an interesting study which adds knowledge to the field

**********

7. PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: Yes: Jian Hu

Reviewer #2: No

Reviewer #3: Yes: Michael E Shy

**********

[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link "View Attachments". If this link does not appear, there are no attachment files.]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com/. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at figures@plos.org. Please note that Supporting Information files do not need this step.

PLoS One. 2022 Oct 4;17(10):e0272097. doi: 10.1371/journal.pone.0272097.r004

Author response to Decision Letter 1


10 Jul 2022

Reviewer #1: The authors have addressed all my concerns. I understand the difficulty of performing the lactate rescue experiments and including Mpz-cre.

Reviewer #2: The authors have made a good effort to address the concerns of the reviewers by amending text and adding new data and the manuscript is much improved. I have a couple of points that should be addressed.

1. In response to a request for comment on prior reports of MNCV slowing in DCA-exposed rodents the authors write “Over the seven weeks of treatment, the chosen dose (500mg/kg daily) was not sufficient to induce the significant reduction of nerve conduction velocity (Fig. 4C) reported previously (36,37), which suggests that nerve conduction is less dependent on mSC lactate in adult rats than in juvenile rats”. This interpretation is not correct as a) reference #37 reports MNCV slowing in adult DCA-exposed mice, not rats and b) reference #36 shows MNCV slowing in adult rats but not juvenile rats after exposure to 500mg/kg. DCA. The authors could simply note that their present MNCV data in adult mice exposed to 500mg/kg DCA does not replicate the prior report (ref #37) that used 1g/kg of DCA in adult mice – perhaps simply due to the lower dose used (note that 500mg/kg in rats as per reference #36 ≠ 500mg/kg in mice due absence of allometric scaling, whereas 500mg/kg in rats = 1g/kg in mice after allometric scaling).

We agree with the reviewer and we modified the results section page 20 line 430 as following: “Over the seven weeks of treatment, the chosen dose (500mg/kg daily) was not sufficient to induce the significant reduction of nerve conduction velocity (Fig. 4C) reported previously at 1g/kg (36). Nevertheless, Rotarod performance decreased in treated mice independently of the genotype (Fig. 4B), suggesting an axonal defect.”

2. The authors provide an interesting axonal size:frequency histogram (Fig S8C) and indicate that there was no difference between control and DCA exposed rats using an unpaired t test. I do not understand this analysis – what data were compared? The paper cited in the response to review used unpaired t test to compare mean axonal diameter, not the size:frequency histogram. Please report values (mean±SD) for MAD in the 2 groups to support any statistical analysis. It is also necessary to report fibers/nerve in order to fully interpret MAD or fiber size:frequency distributions, not just total number of fibers counted.

Raw data including data relative to results presented in Figure S8C are shown in the “raw data” file. We agree with the reviewer that the Student T-test comparing the overall mean of axonal diameter is not accurate. We propose to use a two-way ANOVA test comparing genotypes in all axonal diameter category with a multiple analysis in each category. This analysis was done with Graphpad Prism and is presented in detail in the raw data file for Figure S8C.

We found that, while no significant difference can be found between genotypes regarding each axonal diameter category, there is an overall significant interaction between axonal diameter and genotype. This was noted in the Figure S8C legend : “ Statistical two-way ANOVA analysis followed by a Sidak multiple comparison test comparing mean value for each axonal diameter category showed no significant difference between Control and Mutant mice (genotype P-value = 0.95; see raw data file). However, an overall significant interaction was found between genotype and axonal diameter category (interaction P-value = 0.017; see raw data file).” In addition, we noted this in the results section of the manuscript page 19 line 410: “Axonal diameter distribution was also slightly shifted toward larger axons in Mutant vs Control animals (Fig. S8C). As larger axons display a higher g-ration (Fig. S8A), this change may explain the g-ratio increase. However, the conduction of action potentials along myelinated axons was not altered as the electrophysiological properties of sciatic nerve axons ex vivo were maintained even at very high firing frequencies (Fig. S9, Table S).”

A comment about the statistical analysis was added to the Material and Methods section page 15 line 325: “Statistical analysis Except indicated otherwise, statistical analysis were done using Graphpad Prism (GraphPad Software, San Diego, USA). Statistical significance: *= P value<0.05; **= P value<0.01; ***= P value<0.001.”

Given that the size:frequency histogram (Figure S8C) suggests that DCA-exposed nerve may have a shift towards increased frequency of larger axons and reduced frequency of smaller axons, to what extent does increased axonal MAD contribute to the reported increase in g-ratio rather than the myelin thinning that the authors infer?

We indeed suggested that the decrease in the g-ratio may result from the shift of axon diameter distribution toward larger axons and therefore higher g-ratio.

Reviewer #3: The authors have addressed my concerns. I have no additional concerns about the research ethics or publication ethics. This is an interesting study which adds knowledge to the field

Attachment

Submitted filename: Response to reviewer comments3.docx

Decision Letter 2

David J Schulz

13 Jul 2022

Physiology of PNS axons relies on glycolytic metabolism in myelinating Schwann cells

PONE-D-21-39340R2

Dear Dr. Tricaud,

We’re pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it meets all outstanding technical requirements.

Within one week, you’ll receive an e-mail detailing the required amendments. When these have been addressed, you’ll receive a formal acceptance letter and your manuscript will be scheduled for publication.

An invoice for payment will follow shortly after the formal acceptance. To ensure an efficient process, please log into Editorial Manager at http://www.editorialmanager.com/pone/, click the 'Update My Information' link at the top of the page, and double check that your user information is up-to-date. If you have any billing related questions, please contact our Author Billing department directly at authorbilling@plos.org.

If your institution or institutions have a press office, please notify them about your upcoming paper to help maximize its impact. If they’ll be preparing press materials, please inform our press team as soon as possible -- no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact onepress@plos.org.

Kind regards,

David J Schulz

Academic Editor

PLOS ONE

Additional Editor Comments (optional):

Reviewers' comments:

Acceptance letter

David J Schulz

23 Sep 2022

PONE-D-21-39340R2

Physiology of PNS axons relies on glycolytic metabolism in myelinating Schwann cells.

Dear Dr. Tricaud:

I'm pleased to inform you that your manuscript has been deemed suitable for publication in PLOS ONE. Congratulations! Your manuscript is now with our production department.

If your institution or institutions have a press office, please let them know about your upcoming paper now to help maximize its impact. If they'll be preparing press materials, please inform our press team within the next 48 hours. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information please contact onepress@plos.org.

If we can help with anything else, please email us at plosone@plos.org.

Thank you for submitting your work to PLOS ONE and supporting open access.

Kind regards,

PLOS ONE Editorial Office Staff

on behalf of

Dr. David J Schulz

Academic Editor

PLOS ONE

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 File

    (DOCX)

    S1 Table. Electrophysiological characteristics of control and mutant mice.

    (DOCX)

    S1 Data

    (XLSX)

    S1 Raw images

    (PDF)

    Attachment

    Submitted filename: Response to Reviewers comments2.docx

    Attachment

    Submitted filename: Response to reviewer comments3.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files (supplementary information and raw data files).


    Articles from PLoS ONE are provided here courtesy of PLOS

    RESOURCES